Plain-English translation of NCT05672121 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Age-Related Macular Degeneration research guide โPhase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new gene therapy treatment for neovascular age-related macular degeneration (a serious eye condition that causes vision loss). The medication is given as a single injection directly into the back of the eye. Unlike the regular injections most people with this condition currently receive, this treatment is designed to work long-term from just one dose, potentially reducing how often you need treatment.
People with neovascular age-related macular degeneration typically need repeated injections every month or two to maintain their vision. This trial is exploring whether a one-time gene therapy injection could provide lasting benefit and reduce the treatment burden on patients.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive a single injection of the medication into the back of your eye through a procedure. The trial is testing five different dose levels to find which works best and is safest. You would then be closely monitored over time with eye exams and imaging to see how well the treatment works and to watch for any side effects.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
China